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Abstract
Background: Subclinical cardiovascular disease is prevalent in patients with Metabolic Syndrome (MetSyn). Left ventricular 
(LV) circumferential strain (εCC) and longitudinal strain (εLL), assessed by Speckle Tracking Echocardiography (STE), are 
indices of systolic function: shortening is indicated by negative strain, and thus, the more negative the strain, the better the 
LV systolic function. They have been used to demonstrate subclinical ventricular dysfunction in several clinical disorders.
Objective: We hypothesized that MetSyn is associated with impaired myocardial function, as assessed by STE.
Methods: We analyzed Multi-Ethnic Study of Atherosclerosis (MESA) participants who underwent STE and were evaluated 
for all MetSyn components.
Results: Among the 133 participants included [women: 63%; age: 65 ± 9 years (mean ± SD)], the prevalence of MetSyn 
was 31% (41/133). Individuals with MetSyn had lower εCC and lower εLL than those without MetSyn (-16.3% ± 3.5% vs. 
-18.4% ± 3.7%, p < 0.01; and -12.1% ± 2.5% vs. -13.9% ± 2.3%, p < 0.01, respectively). The LV ejection fraction (LVEF) 
was similar in both groups (p = 0.09). In multivariate analysis, MetSyn was associated with less circumferential myocardial 
shortening as indicated by less negative εCC (B = 2.1%, 95% CI: 0.6-3.5, p < 0.01) even after adjusting for age, ethnicity, 
LV mass, and LVEF). Likewise, presence of MetSyn (B = 1.3%, 95% CI: 0.3-2.2, p < 0.01) and LV mass (B = 0.02%, 
95% CI: 0.01-0.03, p = 0.02) were significantly associated with less longitudinal myocardial shortening as indicated by less 
negative εLL after adjustment for ethnicity, LVEF, and creatinine. 
Conclusion: Left ventricular εCC and εLL, markers of subclinical cardiovascular disease, are impaired in asymptomatic 
individuals with MetSyn and no history of myocardial infarction, heart failure, and/or LVEF < 50%. (Arq Bras Cardiol. 
2014; 102(4):327-335)
Keywords: Atherosclerosis; Metabolic X Syndrome; Diabetes Mellitus / mortality; Ventricular Dysfunction / 
physiopathology; Ethnic Group.
Introduction
Metabolic syndrome (MetSyn) is characterized by a cluster of 
cardiovascular (CV) risk factors including atherogenic dyslipidemia, 
abdominal obesity, hyperglycemia, elevated blood pressure, and 
proinflammatory and prothrombotic state1. It affects about 25% 
of the population, being associated with an increased risk of 
developing diabetes, CV morbidity and mortality2.
Previous studies using carotid intima-media thickness 
measured with ultrasound, coronary artery calcium, Tei index, 
and tissue Doppler have shown the presence of subclinical 
CV disease (CVD) in participants with MetSyn3-13.
Recently, speckle tracking echocardiography (STE) has been 
introduced as a new non-invasive method for assessing left 
ventricular (LV) myocardial shortening or strain. The method is 
angle-independent, does not require contrast agents, and has 
been validated against sonomicrometry and magnetic resonance 
imaging (MRI)14-17. It has been used to demonstrate subclinical 
ventricular dysfunction in various clinical disorders18-22.
The purpose of this study was to evaluate the use of STE 
to assess myocardial strain as a marker of LV systolic function 
in an asymptomatic population with MetSyn and LV ejection 
fraction (LVEF) ≥ 50%. We hypothesized that MetSyn is 
associated with impaired LV circumferential strain (εCC), as 
well as with LV longitudinal strain (εLL).
Methods
Study population
The purpose of the Multi-Ethnic Study of Atherosclerosis 
(MESA), a multicenter population-based study, is to 
investigate mechanisms underlying the development and 
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progression of subclinical CVD in asymptomatic men and 
women from four different ethnic groups – Caucasian, 
African-American, Hispanic, and Chinese23. Between 
July/2008 and June/2009, during MESA follow-up evaluation, 
162 consecutive participants in the Baltimore cohort of 
MESA were invited to undergo an echocardiographic study. 
We included participants who underwent echocardiography, 
tagged MRI (reference method for εCC), and evaluation for all 
MetSyn components. Participants who had more than two LV 
segments not analyzable on STE in short-axis- or 4-chamber 
view were excluded from the strain analysis. Exclusion criteria 
also included a history of myocardial infarction (MI), heart 
failure (HF) and/or LVEF < 50%. The institutional review 
board of the Johns Hopkins University approved the study, 
and participants provided written informed consent.
Metabolic syndrome definition
Metabolic syndrome was defined according to revised 
National Cholesterol Education Program Adult Treatment Panel 
(NCEP ATP) III criteria24. Participants having at least three of the 
following criteria were considered as having MetSyn: fasting 
plasma glucose (FPG) ≥ 100 mg/dL; triglycerides ≥ 150 mg/dL; 
HDL-cholesterol < 40 mg/dL in men and < 50 mg/dL in women; 
abdominal obesity [waist circumference (WC) ≥ 102 cm in men 
and ≥ 88 cm in women]; and blood pressure ≥ 130/85 mm Hg. 
The revised NCEP definition still includes patients being treated 
for dyslipidemia, systemic hypertension, or hyperglycemia.
Risk factors
Participants completed standardized medical history 
questionnaires ascertaining medication use and previous 
diagnoses and provided samples for quantification of FPG, 
lipids, and creatinine25. Waist circumference was measured 
at the level of the umbilicus using a standard tape measure. 
Resting blood pressure was measured three times in a 
seated position using a Dinamap model Pro 100 automated 
oscillometric sphygmomanometer (Critikon, Tampa, FL, 
USA). The average of the last two measurements was used 
in the analysis. Arterial hypertension was diagnosed using 
the VII Joint National Committee criteria26. Diabetes was 
defined as a FPG ≥126 g/mL or use of insulin or of an oral 
hypoglycemic agent. Smoking status was defined as current 
smoking or no smoking.
Echocardiography and speckle tracking
Examinations were performed by expert sonographers, 
and reviewed off-line by one reader (ALCA). Two-dimensional 
echocardiograms were recorded during breath-holds using 
an Artida scanner (Toshiba Medical Systems Corp, Tochigi, 
Japan) at the time of MESA follow-up evaluation. The images 
were acquired from the short-axis view of the left ventricle 
at the papillary muscle level and from the apical 4-chamber 
view, and stored digitally. The images were recorded 
using B-mode harmonic images and adjusting transducer 
frequencies (1.7-3.5 MHz), frame rate (40-80 frames per 
second), focus (midventricular), sector width (as narrow as 
possible), sector depth (minimal) and gain in order to optimize 
myocardial image quality. The echocardiographic recordings 
were analyzed with STE software (Toshiba 2D Wall Motion 
Tracking software, Toshiba Medical Systems). The manual 
counterclockwise tracing of endocardial and epicardial borders 
in the mid-LV short-axis image at end-systole was followed 
by automatic drawing of a mid-wall tracking line14. A similar 
approach was made in the 4-chamber recording, starting at 
the lateral corner of the mitral annulus, at the end-diastole. 
STE software uses the ‘sum of squared differences’ method 
to find the most similar speckle pattern of the 2D template in 
two subsequent frames27. Strain (ε, %) was calculated as the 
change in regional length relative to its end-diastolic length; 
ε = (L(t) – L0)x100/L0, where L(t) is the length at time t, and L0 is 
the segment length at the onset of QRS. Global εCC (Figure 1) 
and εLL (Figure 2) are represented by the peak of average 
strain. As ε reflects myocardial shortening, a more negative 
value indicates more shortening. The mid-ventricular short axis 
level and the 4-chamber view of the left ventricle were divided 
according to the American Society of Echocardiography 
recommendation28. Segments were excluded from analyses 
due to dropouts, motion artifacts, reverberations, or bad 
tracking quality due to manual assessment. 
Magnetic Resonance Imaging: Tagged MRI protocol and 
strain measurement
Participants underwent MRI and echocardiography on 
the same day. Cardiac MRI scan was acquired using 1.5T MR 
scanners [Signa LX or CVi (GE Medical Systems, Waukesha, 
WI, USA)]. Images were obtained using a segmented k-space 
and ECG-triggered SPGR pulse sequence. After acquisition 
of standard scout images, 2- and 4-chamber cine MR 
images were acquired. Short-axis cine images were then 
obtained with retrospective gating and temporal resolution of 
≤ 50 msec, from above the mitral valve plane to the LV apex29. 
Left ventricular structural parameters (end-systolic and 
end-diastolic volumes, LV mass) and LVEF were measured 
using standard commercially available software (MASS 4.2, 
MEDIS, Leiden, The Netherlands), as previously described29. 
Left ventricular mass index was defined as LV mass divided by 
body surface area. After completing the standard protocol, three 
tagged short-axis slices (base to apex) were obtained. Parallel 
striped tags were prescribed in two orthogonal orientations (0° 
and 90°) using ECG-triggered fast gradient echo sequence with 
spatial modulation of magnetization. The parameters for tagged 
images were as follows: field of view, 40 cm; slice thickness, 
7 to 8 mm; repetition time, 6 ms; echo time, 3.0 ms; flip 
angle, 10° to 12°; phase encoding views, 128 with six phase 
encoding views per segment; temporal resolution, 35 msec; 
and tag spacing, 7 mm. Circumferential strain was measured 
using HARP method embedded in MATLAB software (The 
MathWorks, Natick, MA, USA)30.
Reproducibility
Thirty studies were randomly selected for the assessment 
of intra- and inter-observer variability of εCC and εLL on STE. 
To test intra-observer variability, a single observer (ALCA) 
analyzed the data twice with a minimal interval of 30 days. 
To test inter-observer variability, a second observer (EYC) 
analyzed the data without knowing the first observer’s 
measurements.
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Figure 1 – Representative LV εCC curve from a participant without MetSyn. Different colors depict different myocardial segments. The white strain curve represents the 
global circumferential peak strain. ES: end-systole; εCC: circumferential strain; LV: left ventricle.
Figure 2 – Representative LV εLL curve from a participant with MetSyn. Different colors depict different myocardial segments. The white strain curve represents the global 
longitudinal peak strain. ES: end-systole; εLL: longitudinal strain; LV: left ventricle; LA: Left atrium; RV: Right ventricle; RA: Right atrium; MV: Mitral valve
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Statistical analysis
Data are shown as mean ± standard deviation (SD) for 
continuous variables and as proportions for categorical 
variables. Student’s t test was used to assess differences in 
continuous variables between the groups studied, whereas 
chi-square test was used for categorical analysis. Univariate 
analysis was performed to assess the relationship of εCC and 
εLL with the variables of interest. Multiple linear regression 
(MLR) analysis was performed to study the association 
between εCC assessed on echocardiography and variables 
with a p value < 0.10 in the univariate analysis, and 
variables with biological plausibility to interfere with LV 
strain. The same approach was used for εLL measured on 
echocardiography and for εCC measured on tagged MRI. 
In addition, models of MLR analysis were created, using 
the stepwise variable selection procedures, to evaluate 
the potential association of εCC and εLL on STE and 
individual MetSyn components, as well as all the possible 
term interactions between the MetSyn components. 
Intra-observer and inter-observer variability was assessed 
by using intraclass correlation coefficient. A two-tailed p 
value < 0.05 was considered statistically significant for all 
analyses. Statistical analyses were performed using the SPSS 
18 statistical software package (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
Echocardiography was obtained in 162 consecutive MESA 
participants. Compared to the entire MESA cohort, this study 
cohort had higher HDL-cholesterol (57.3 ± 19.0 mg/dL versus 
52.7 ± 15.6 mg/dL, p < 0.01) and a greater percentage of 
females (63% versus 47%, p < 0.05). Due to enrollment 
characteristics of the study site, only black and white study 
participants were included.
Twenty-six (16%) participants were excluded from the 
analysis because of poor echocardiographic image quality, 
and three others (1.9%) because of missing data about at 
least one of the MetSyn components. No participant was 
excluded because of a history of MI, HF, or LVEF < 50%. 
The final study population consisted of 133 participants 
(women: 63%, mean age = 65 ± 9 years).
The prevalence of MetSyn in this sample was 31% 
(41 MetSyn in 133 participants). Table 1 lists the clinical and 
demographic characteristics of the participants according to the 
MetSyn status. The LVEF measured by use of MRI was 61 ± 5%.
Data reproducibility
The inter-observer and intra-observer intraclass 
correlation coefficients (ICC) for εLL were 0.84 (p < 0.01) 
and 0.87 (p < 0.01), respectively. Those for εCC were 
0.86 (p < 0.01) and 0.85 (p < 0.01), respectively.
Metabolic syndrome and LV circumferential strain on STE
Table 2 shows the echocardiographic and MRI data of 
participants according to the MetSyn status.
The LVEF was similar in both groups (p = 0.09). However, 
individuals with MetSyn had lower εCC on STE than those without 
MetSyn (εCC = -16.3% ± 3.5% versus -18.4% ± 3.7, p < 0.01). 
Men with MetSyn had lower εCC on STE as compared with those 
without MetSyn (-15.5% versus -18.6%, p < 0.01). Women with 
MetSyn tended to have lower εCC (-16.8% versus -18.3%), but 
with no significance (p = 0.11). The εCC was similar in women 
and men with MetSyn (p > 0.05).
Table 1 – Clinical and demographic data of participants according to the MetSyn status
Variable Without MetSyn (n = 92) Mean ± SD With MetSyn (n = 41) Mean ± SD p value
Age (year) 65 ± 8 66 ± 9 0.27
Creatinine (mg/dL) 1.0 ± 0.2 1.0 ± 0.3 0.15
Gender (Female, %) 63% 63% 0.97
Ethnicity (Caucasian, %) 60% 44% 0.09
Smoking (current, %) 8% 10% 0.69
Weight (Kg) 77 ± 17 91 ± 18 < 0.01
BMI (Kg/m2) 28 ± 5 32 ± 4 < 0.01
Total cholesterol (mg/dL) 197 ± 44 177 ± 39 0.01
LDL-cholesterol (mg/dL) 116 ± 39 101 ± 36 < 0.05
Any lipid-lowering medication (Yes, %) 28% 47% < 0.05
Waist circumference (cm)* 93 ± 13 107 ± 14 < 0.01
Glucose (mg/dL)* 93 ± 16 107 ± 24 < 0.01
Triglycerides (mg/dL)* 94 ± 46 151 ± 71 < 0.01
HDL-cholesterol (mg/dL)* 62 ± 20 46 ± 11 < 0.01
Hypertension (Yes, %)* 42% 80% < 0.01
MetSyn: Metabolic Syndrome; SD: standard deviation; BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; *: Metabolic Syndrome component.
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In univariate analysis, εCC on STE was significantly related to 
the presence of MetSyn (p < 0.01), weight (p < 0.01), body 
mass index (BMI) (p < 0.05), and WC (p < 0.01) (Table 3). 
The MLR analysis included variables that were significant 
in the univariate analysis (MetSyn), as well as variables with 
biological plausibility to change εCC, such as LVEF, LV mass, 
age, and ethnicity. Weight, BMI, and WC were excluded from 
the model because they are directly or indirectly related to 
the MetSyn definition. In this model, MetSyn was significantly 
related to εCC even after adjustment for covariates (B = 2.1%; 
95% CI: 0.6-3.5; p < 0.01) (Table 3).
In another model of MLR analysis, LVEF, LV mass, age, 
and ethnicity were maintained, and the MetSyn variable 
was replaced for all five components of MetSyn. In that 
case, only WC remained significantly associated with εCC 
(B = 2.0%; 95% CI: 0.7-3.3; p < 0.01, stepwise method). 
Again, using all the MetSyn components and all the possible 
interaction terms between them, only WC maintained 
significance (B = 2.0%; 95% CI: 0.7-3.3; p < 0.01).
The εCC measured on echocardiography changed from 
-18.7% in participants with ≤ one MetSyn component to 
-18.0% in participants with two MetSyn components and 
to -16.3% in those with ≥ three MetSyn criteria (p < 0.01).
The WC component was present in 95.1% of the participants 
with MetSyn, while blood pressure, HDL-cholesterol, FPG, 
and triglycerides were present in 87.8%, 61.0%, 46.3%, and 
43.9%, respectively. On the other hand, the WC component 
was present in 45% of the participants without MetSyn.
Metabolic syndrome and LV circumferential strain on 
tagged MRI
Similarly to STE results, individuals with MetSyn had lower 
εCC on tagged MRI than those without MetSyn (εCC = -15.8% 
± 3.3% versus -17.6% ± 2.3%, p < 0.01) (Table 2).
On univariate analysis, the presence of MetSyn, weight, WC, 
LVEF, and LV mass were significantly related to εCC on tagged 
MRI. On MLR analysis, both the presence of MetSyn (B = 1.3%; 
95% CI: 0.3-2.4; p = 0.02) and LV mass (B = 0.02%; 
95% CI: 0.01-0.03; p = 0.03) remained significant. 
Metabolic syndrome and LV longitudinal strain
Individuals with MetSyn had lower εLL as compared with those 
without MetSyn (-12.1% ± 2.5% versus -13.9% ± 2.3, p < 0.01) 
(Table 2). This result was consistent for men and women. The εLL 
was similar in women and men with MetSyn (p > 0.05).
On univariate analysis, εLL was significantly related 
to MetSyn, weight, BMI, WC, ethnicity, LV mass, LVEF, 
creatinine, hypertension status, diabetes status, and 
triglycerides (Table 4). The MLR analysis included presence 
of MetSyn, LV mass, LVEF, ethnicity, and creatinine, which 
were significant in the univariate analysis. Weight, BMI, WC, 
triglycerides, hypertension, and diabetes status were excluded 
from the model because they are directly or indirectly related 
to the MetSyn definition. Presence of MetSyn (B = 1.3%; 
95% CI: 0.3-2.2; p < 0.01) and LV mass (B = 0.02%; 95% 
CI: 0.01-0.03; p = 0.02) were independently related to εLL 
in the model (Table 4). The results were similar when using 
LV mass indexed by height in meters: presence of MetSyn 
(B = 1.3%; 95% CI: 0.3-2.2; p < 0.01) and LV mass/height 
(B = 0.03%; 95% CI: 0.01-0.06; p = 0.04).
In another model of MLR analysis, we maintained 
LVEF, LV mass, ethnicity, and creatinine, and replaced the 
MetSyn variable for all five components of MetSyn. With 
this approach, LV mass (B = 0.02%, p < 0.01), ethnicity 
(B = 1.0%, p = 0.02), and FPG component (B = 1.2%, 
p = 0.03) remained as independent predictors of εLL 
(stepwise method). In a model using LV mass, ethnicity, the 
five MetSyn components, and all the possible interactions 
between terms (stepwise method), LV mass (B = 0.02%; 
95% CI: 0.01-0.03; p < 0.01), ethnicity (B = 0.9%; 95% 
CI: 0.1-1.8; p = 0.03), and the interaction term WC*FPG 
(B = 1.5%; 95% CI: 0.3-2.7; p = 0.01) remained significant. 
The εLL changed from -14.2% in participants with ≤ one 
MetSyn component, to -13.4%, in participants with two, and 
to -12.1% in those with ≥ three MetSyn criteria (p < 0.01).
Discussion
In our data, MetSyn, as defined by NCEP ATP III, was 
associated with reduced myocardial function as indicated 
Table 2 – Echocardiography and MRI data of participants according to the MetSyn status
Variable Without MetSyn (n = 92) Mean ± SD With MetSyn (n = 41) Mean ± SD p value
εCC (%) [STE] -18.4 ± 3.7 -16.3 ± 3.5 < 0.01
εCC (%) [MRI] -17.6 ± 2.3 -15.8 ± 3.3 < 0.01
εLL (%) [STE] -13.9 ± 2.3 -12.1 ± 2.5 < 0.01
LVEF (%) [MRI] 61 ± 5 59 ± 4 0.09
LV mass (g) [MRI] 120 ± 28 136 ± 35 < 0.01
LV mass index (g/m2) [MRI] 65 ± 11 68 ± 13 0.18
LVID (mm) [Echo] 46 ± 6 44 ± 5 0.15
εCC:circumferential strain; εLL: longitudinal strain; LV: left ventricle; LVEF: LV ejection fraction; LVID: LV internal diameter; MetSyn: Metabolic Syndrome; MRI: magnetic 
resonance imaging; STE: speckle tracking echocardiography.
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Table 3 – Univariate and multivariate analysis – Dependent variable: εCC on STE
Independent variables
Univariate analysis Multivariate analysis
B coeff (%) 95%CI p value B coeff (%) 95%CI p value
Presence of MetSyn 2.07 (0.72;3.42) < 0.01 2.06 (0.59;3.52) < 0.01
Weight (Kg) 0.05 (0.01;0.08) < 0.01 - - -
Waist circumference (cm) 0.07 (0.03;0.11) < 0.01 - - -
BMI (Kg/m2) 0.15 (0.03;0.26) < 0.05 - - -
Age (years) 0.02 (-0.06;0.09) 0.60 0.01 (-0.07;0.08) > 0.05
Ethnicity (Caucasian) -0.57 (-1.86;0.72) 0.60 -0.87 (-2.17;0.43) > 0.05
LV mass (g) 0.02 (-0.01;0.04) 0.17 0.01 (-0.01;0.03) > 0.05
LVEF (%) -0.03 (-0.13;0.07) 0.51 -0.01 (-0.11;0.10) > 0.05
Gender (female) 0.17 (-1.16;1.51) 0.80 - - -
Creatinine (mg/dL) -0.18 (-2.97;2.62) 0.90 - - -
Smoking status (current) -0.38 (-2.73;1.97) 0.75 - - -
Hypertension (Yes) 0.16 (-1.14;1.47) 0.81 - - -
Diabetes (Yes) 0.80 (-1.00;2.60) 0.38 - - -
FPG (mg/dL) 0.03 (-0.01;0.06) 0.09 - - -
Total cholesterol (mg/dL) 0.01 (-0.01;0.02) 0.95 - - -
LDL-cholesterol (mg/dL) -0.01 (-0.02;0.01) 0.72 - - -
HDL-cholesterol (mg/dL) -0.01 (-0.04;0.03) 0.87 - - -
Triglycerides (mg/dL) 0.01 (-0.01;0.02) 0.10 - - -
BMI: body mass index; εCC: circumferential strain; FPG: fasting plasma glucose; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LV: left ventricle; 
LVEF: LV ejection fraction; MetSyn: Metabolic Syndrome; MRI: magnetic resonance imaging.
by an impaired εCC and εLL in a sample of MESA participants. 
This result becomes even more important considering 
that this study sample was constituted by asymptomatic 
individuals with no history of MI, HF, and/or LVEF<50%. 
These findings could indicate presence of subclinical CVD 
in that population. The strength of those relationships 
was maintained even after adjusting for age, ethnicity, 
creatinine, LVEF, and LV mass.
Subclinical CVD has been demonstrated in subjects 
with MetSyn3-8. Gong et al. have used tissue Doppler 
to analyze εLL in Chinese participants with MetSyn
13. 
Consistent with our findings in African-American and 
Caucasian participants, they have demonstrated that mean 
systolic εLL was lower in participants with MetSyn than 
in controls. In our study, using STE analysis, longitudinal 
as well as circumferential myocardial functions were 
reduced, as indicated by lower εLL and εCC in participants 
with MetSyn as compared with those without MetSyn. 
As MetSyn is more prevalent in African-Americans and 
Caucasians than in the Chinese population, a more general 
conclusion can be drawn from our study. Furthermore, 
strain measured by using Doppler has some limitations 
such as poor reproducibility, angle dependency, and 
signal noise31.
Waist circumference has been cited as a marker of central 
obesity, carrying a stronger association with health risk 
indicators32. Our data support this concept, because when 
all five components of MetSyn and all possible interactions 
between terms were analyzed on MLR analysis, only WC 
remained significantly associated with εCC on STE.
The strain difference between participants with and 
without MetSyn was small. Differences in circumferential 
and longitudinal myocardial shortening are typically small, 
particularly in samples of asymptomatic individuals20,33-35. 
Our εCC values were higher than εLL in concordance with 
other results36. Participants with MetSyn had lower total and 
LDL-cholesterol than those without MetSyn, probably due 
to higher usage of lipid-lowering medication.
Our findings indicate that εCC was somewhat underestimated 
on MRI, when compared with εCC on STE, independently of 
the presence of MetSyn. The lower temporal resolution of 
tagged MRI could explain this difference14,15.
The use of STE could help to improve patient care while 
providing early identification of subclinical disease37. In agreement 
with other reports3-6,8,11-13, our results support the association 
between MetSyn and subclinical CVD. Thus, individuals with 
MetSyn should be encouraged to improve their quality of life 
and control all CV risk factors, particularly abdominal obesity.
Limitations
Because of the cross-sectional design of our study, a causal 
relationship between MetSyn and strain cannot be established 
accurately. More studies are necessary to evaluate the clinical 
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Table 4 – Univariate and multivariate analysis – Dependent variable: εLL on STE
Independent variables
Univariate Analysis Multivariate analysis
B coeff (%) 95%CI p value B coeff (%) 95%CI P value
Presence of MetSyn 1.73 (0.83;2.64) < 0.01 1.25 (0.32;2.19) < 0.01
Weight (Kg) 0.04 (0.02;0.07) < 0.01 - - -
Waist circumference (cm) 0.04 (0.01;0.07) < 0.01 - - -
BMI (Kg/m2) 0.11 (0.03;0.18) < 0.01 - - -
Age (years) 0.02 (-0.03;0.08) 0.37 - - -
Ethnicity (Caucasian) 1.11 (0.24;1.97) 0.01 0.85 (-0.0;1.71) > 0.05
LV mass (g) 0.02 (0.01;0.04) < 0.01 0.02 (0.01;0.03) 0.02
LVEF (%) -0.04 (-0.11;0.03) 0.21 -0.02 (-0.08;0.05) > 0.05
Gender (female) 0.59 (-0.31;1.50) 0.20 - - -
Creatinine (mg/dL) 2.10 (0.23;3.97) 0.03 0.29 (-1.74;2.32) > 0.05
Smoking status (current) 1.23 (-0.35;2.82) 0.13 - - -
Hypertension (Yes) 0.97 (0.10;1.84) 0.03 - - -
Diabetes (Yes) 1.55 (0.35;2.75) 0.01 - - -
FPG (mg/dL) 0.02 (-0.01;0.04) 0.12 - - -
Total cholesterol (mg/dL) -0.01 (-0.02;0.01) 0.33 - - -
LDL-cholesterol (mg/dL) -0.01 (-0.02;0.01) 0.19 - - -
HDL-cholesterol (mg/dL) -0.01 (-0.04;0.01) 0.26 - - -
Triglycerides (mg/dL) 0.01 (0.01;0.02) 0.02 - - -
BMI: body mass index; εCC: circumferential strain; FPG: fasting plasma glucose; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LV: left ventricle; 
LVEF: LV ejection fraction; MetSyn: Metabolic Syndrome; MRI:magnetic resonance imaging.
relevance of our data. Although strain parameters are not 
disease-specific, strain has been introduced as a sensitive marker 
of LV systolic function18-21. The participants were asymptomatic 
for HF, and did not undergo exercise stress test to exclude 
disease at the time of the echocardiographic evaluation. 
Because reproducibility is better for two-dimensional strain, 
the strain rate was not analyzed in this study.
Conclusion
These results indicate that LV εLL and εCC, markers of subclinical 
CVD, are impaired in asymptomatic individuals with MetSyn and 
no history of MI, HF and/or LVEF<50%. Our findings support 
strict control of each risk component of MetSynd, mainly WC. 
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